The curative potential of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have transformed hepatology in recent years. However, the challenge of identifying more people living with HCV remains, and further progress is needed with other forms of viral…
Researchers at EF Clif identify three different clinical courses for the first time, in patients with acute decompensated cirrhosis without acute-on-chronic liver failure (ACLF). July 14, 2020 – A clinical study led by the European Foundation for the Study of…
ClarivateTM Analytics released the 2020 update of its Journal Citation Reports©, including the much anticipated 2019 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2019 impact factor of 20.582, up from the 2018…
This is the ideal opportunity for you to learn from some of the biggest names in hepatology and meet them in an engaging & interactive setting!
EASL has been actively working to beat liver disease, including NAFLD & NASH, through its schools and key event, the NAFLD Summit. EASL has also developed a Policy Statement on the measures required to prevent and treat this common progressive…
Be a part of this innovative and engaging digital event for the liver community to connect and learn via cutting-edge content. Enjoy three days of immersive and lively exchanges at the Digital International Liver Congress™ 2020 from 27 to 29…
The EASL members' General Assembly, usually held within the framework of the International Liver Congress™, will take place as an online meeting on Monday, 29 June 2020 at 17:00–19:00 CET. The General Assembly is a key opportunity for EASL members…
In a webinar jointly run by EASL and the World Health Organization (WHO), virology and hepatology experts compared strategies in coping during the current pandemic. They described a rise in innovative, cooperative mitigating approaches, but noted that essential hepatitis and…
